Formula For Our Success
Kineta's® area of specialization is translational research. We have refined a process of selecting high caliber early stage drug programs and rapidly advancing them into phase 1 human clinical trials.
Our scientists are working on treatments for infectious, inflammatory and autoimmune diseases and on pain relief with a focus on developing novel drugs that work in concert with the immune system. Our programs have broad pharmaceutical applications and are advancing into the clinical pipeline during the current unprecedented wave of patent expirations. This environment provides tremendous market demand for our pipeline of early clinical programs.
All of our programs available for investment are designed to reach valuable inflection points within three to four years at which point they are made available for license to the larger pharmaceutical industry. We are engaged in on-going conversations with larger biotechnology and pharmaceutical companies in regards to potential partnerships. The intellectual property associated with each program is held in a limited liability corporation (LLC) protecting investor value, simplifying transactions and maintaining stability of our parent company. We believe our business model provides tremendous opportunity for the advancement of our drug programs and for strong returns to our investors.
Kineta is a privately held corporation that seeks investors, industry partners and patient advocacy groups who share our vision of improving human health through the development of breakthrough medicines. Our company has an exacting focus on the achievement of early clinical milestones and is designed to be a sustainable business enterprise. We encourage health-focused research foundations, private equity investment groups and trusts to learn more about Kineta. For additional information contact our business team at email@example.com or by calling 206-378-0400